November is Pancreatic Cancer Awareness Month
November 08, 2023 04:00 ET
|
EnGeneIC
SYDNEY, Australia and NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Pancreatic ductal adenocarcinoma (PDAC), which accounts for >90% of pancreatic tumors, is one of the most lethal malignancies and...
The Global Market for Bispecific Antibody Therapeutics Contract Manufacturing 2023-2030: Driven by Demand for Innovative Therapies and Promising Results Seen in Clinical Development
November 06, 2023 09:04 ET
|
Research and Markets
Dublin, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Bispecific Antibody Therapeutics Contract Manufacturing Market 2023-2030" report has been added to ResearchAndMarkets.com's offering. The...
China Bispecific Antibodies Market and Clinical Pipeline Insight Report 2023-2028: Akeso are Leading the Way and Gaining Global Recognition for their Innovative Clinical Candidates
November 06, 2023 04:23 ET
|
Research and Markets
Dublin, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The "China Bispecific Antibodies Market and Clinical Pipeline Insight 2028" drug pipelines has been added to ResearchAndMarkets.com's offering. The...
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 03, 2023 06:00 ET
|
Turnstone Biologics Corp.
Posters showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for solid tumors.
Global CD3 Antibodies Market 2023-2028: New-Generation CD3 Antibodies Targeting Diverse Indications Gain Ground
November 02, 2023 07:43 ET
|
Research and Markets
Dublin, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The "Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. ...
Wistar Scientists Engineer New NK cell Engaging Immunotherapy Approaches to Target and potentially Treat recalcitrant Ovarian Cancer
November 01, 2023 14:54 ET
|
The Wistar Institute
PHILADELPHIA, PA, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The Wistar Institute’s David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center (VIC) and W.W. Smith...
Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM)
November 01, 2023 12:46 ET
|
Siren Biotechnology, Inc.
Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM)
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
October 31, 2023 09:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, will be reporting novel findings for its lead product, pepinemab, in two...
Outpace Bio to Present New Data on Tumor-restricted IL-12 Designed Leveraging OutSmart Technology to Enhance Solid Tumor T Cell Therapies at SITC 2023
October 31, 2023 09:00 ET
|
Outpace Bio
Seattle, WA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Outpace Bio, a cell therapy company that is solving the major barriers to curing solid tumors with AI-powered protein design, today announced it will...
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
October 26, 2023 09:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, today reports novel findings for its lead product, pepinemab, in a...